Bicycle Therapeutics

+$0.93 (+6.20%) Today
$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BCYC and other ETFs, options, and stocks.

About BCYC

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles.

CEO
Kevin Lee
Employees
119
Headquarters
Cambridge, Cambridgeshire
Founded
2009

BCYC Key Statistics

Market cap
472.30M
Price-Earnings ratio
—
Dividend yield
—
Average volume
540.09K
High today
$16.13
Low today
$14.44
Open price
$15.00
Volume
577.48K
52 Week high
$62.08
52 Week low
$14.43

BCYC News

BenzingaMay 27

Bicycle Therapeutics's Return On Capital Employed Overview

Benzinga Pro data, Bicycle Therapeutics BCYC reported Q1 sales of $3.86 million. Earnings fell to a loss of $27.56 million, resulting in a 52.82% decrease from

BCYC Earnings

-$0.93
-$0.62
-$0.31
-$0.00
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Estimated
— per share
Actual
Expected Aug 4, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure